scholarly journals Enhancement of the antibiotic activity of aminoglycosides by extracts from Anadenanthera colubrine (Vell.) Brenan var. cebil against multi-drug resistant bacteria

2015 ◽  
Vol 30 (11) ◽  
pp. 1289-1292 ◽  
Author(s):  
Humberto M. Barreto ◽  
Kivia M.R.N. Coelho ◽  
Josie H.L. Ferreira ◽  
Bernadete H.C. dos Santos ◽  
Aislan P.L. de Abreu ◽  
...  
2007 ◽  
Vol 30 (9) ◽  
pp. 805-812 ◽  
Author(s):  
J.L. Del Pozo ◽  
M. Alonso ◽  
C.R. Arciola ◽  
R. Gonzalez ◽  
J. Leiva ◽  
...  

Microorganisms universally attach to surfaces, resulting in biofilm formation. These biofilms entail a serious problem in daily clinical practice because of the great prevalence of implantable device-related infections. Differences in antibiotic activity against planktonic and sessile bacteria may relate to clinical failures in the treatment of biofilm-related infections (BRI). Bacteriophages have several characteristics that make them potentially attractive therapeutic agents in some selected clinical settings, like for example BRI. They are highly specific and very effective in lysing targeted bacteria, moreover, they appear to be safe for humans. Many studies have shown the potential of phages for the treatment of infectious diseases in plants and animals, including infections with highly drug-resistant bacteria. The therapeutic use of bacteriophages, possibly in combination with antibiotics, may be a valuable approach in BRI. However, many important questions still remain that must be addressed before phages can be endorsed for therapeutic use in humans.


2017 ◽  
Vol 15 (34) ◽  
pp. 7173-7180 ◽  
Author(s):  
Simon J. Mountford ◽  
Biswaranjan Mohanty ◽  
Kade D. Roberts ◽  
Heidi H. Yu ◽  
Martin J. Scanlon ◽  
...  

The synthesis and NMR structure of a polypeptin, a depsipeptide that shows anti-bacterial activity against drug resistant bacteria has been achieved.


2021 ◽  
Vol 9 (14) ◽  
pp. 3136-3142
Author(s):  
Quanchao Du ◽  
Xiangyang Wu ◽  
Wuguo Bi ◽  
Bengang Xing ◽  
Edwin K. L. Yeow

A NIR-light activated upconversion nanocrystal transfers energy to dye molecules that photocatalyze the bioorthogonal conjugation of the antibiotic to drug-resistant bacteria for enhanced treatment efficacy.


Author(s):  
E.A. Martis ◽  
G M Doshi ◽  
G V Aggarwal ◽  
P P Shanbhag

With the emergence of newer diseases, resistant forms of infectious diseases and multi-drug resistant bacteria, it has become essential to develop novel and more effective antibiotics. Current antibiotics are obtained from terrestrial life or made synthetically from intermediates. The ocean represents virtually untapped resource from which novel antibiotic compounds can be discovered. It is the marine world that will provide the pharmaceutical industry with the next generation of antibiotics. Marine antibiotics are antibiotics obtained from marine organisms. Scientists have reported the discovery of various antibiotics from marine bacteria (aplasmomycin, himalomycins, and pelagiomycins), sponges (Ara C, variabillin, strobilin, ircinin-1, aeroplysin, 3,5-dibromo-4-hydroxyphenylacetamide), coelenterates (asperidol and eunicin), mollusks (laurinterol and pachydictyol), tunicates (geranylhydroquinone and cystadytins), algae (cycloeudesmol, aeroplysinin-1(+), prepacifenol and tetrabromoheptanone), worms (tholepin and 3,5-dibromo-4-hydroxybezaldehyde), and actinomycetes (marinomycins C and D). This indicates that the marine environment, representing approximately half of the global diversity, is an enormous resource for new antibiotics and this source needs to be explored for the discovery of new generation antibiotics. The present article provides an overview of various antibiotics obtained from marine sources.


Author(s):  
Daniel Berman

How can we prevent the rise of resistance to antibiotics? In this video, Daniel Berman,  Nesta Challenges, discusses the global threat of AMR and how prizes like the Longitude Prize can foster the development of rapid diagnostic tests for bacterial infections, helping to contribute towards reducing the global threat of drug resistant bacteria. Daniel outlines how accelerating the development of rapid point-of-care tests will ensure that bacterial infections are treated with the most appropriate antibiotic, at the right time and in the right healthcare setting.


Author(s):  
Ryunosuke Hakuta ◽  
Yousuke Nakai ◽  
Tsuyoshi Hamada ◽  
Yusuke Nomura ◽  
Tomotaka Saito ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document